of gene-expression profiling to assess cancer prognosis and guide therapy;on the sidelines, we may very well find ourselves in the scientificthe use of genotyping to stratify patients according to the risk of a disease,“reruns” instead of at the forefront of novel, cutting-edge research. such as prolonged QT interval syndrome or myocardial infarction; the use Stephan Ziegeler, M.D., Byr